peginterferon + ribavirin + camel milk

Peginterferon + ribavirin + camel milk is an investigational combination therapy for the treatment of chronic hepatitis C virus (HCV) infection. [4-1, 4-3] This therapeutic approach adds camel milk as an adjunctive treatment to the standard of care, which involves peginterferon alfa (a pegylated biologic immunomodulator) and ribavirin (a small molecule antiviral). [4-1, 4-3, 4-4, 11] The combination targets the hepatitis C virus through multiple mechanisms: peginterferon stimulates the body's immune response against the virus, while ribavirin directly inhibits viral replication. [8, 3, 4] Camel milk contributes anti-inflammatory and immunomodulatory effects, reportedly by reducing proinflammatory markers such as TNF-α and TGF-β1, and increasing levels of anti-inflammatory cytokines like IL-10, antioxidants, and anti-apoptotic proteins. [4-6, 4-7, 15] Clinical studies have investigated this combination in patients with HCV genotypes 2, 3, and 4. [4-4, 2]

Brand names

Pegasys + Copegus

Other names

PEG-IFN/RBV + camel milk